Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 05 2018 - 4:05PM
Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical
company focused on developing novel therapeutic antibodies for the
treatment of migraine, today reported that the Compensation
Committee of Alder’s Board of Directors granted a non-qualified
stock option to purchase an aggregate of 40,000 shares of Alder’s
common stock to a new employee under Alder’s 2018 Inducement Award
Plan, effective October 1, 2018.
The stock option will vest with respect to 25% of the shares
underlying the option one year after the employee’s employment
start date and the remaining 75% of the shares underlying the
option will vest in equal monthly installments over the 36 month
period following the one year anniversary of the employee’s
employment start date, subject to the employee’s continued service
to Alder through each relevant vesting date. The option has a ten
year term and an exercise price of $14.865 per share, which is
equal to the closing price of Alder’s common stock on October 1,
2018.
The stock option was granted as an inducement material to the
employee’s entering into employment with Alder in accordance with
Nasdaq Listing Rule 5635(c)(4).
About Alder BioPharmaceuticals, Inc.Alder
BioPharmaceuticals is a clinical-stage biopharmaceutical company
focused on transforming the migraine treatment paradigm through the
discovery, development and commercialization of novel therapeutic
antibodies. Alder’s lead product candidate, eptinezumab, is a
pivotal-stage monoclonal antibody (mAb) that inhibits calcitonin
gene-related peptide (CGRP). Eptinezumab is currently in late-stage
clinical development and, if approved, will be the first-to-market
infusion therapy for migraine prevention. Alder is also developing
ALD1910, a preclinical mAb that inhibits pituitary adenylate
cyclase-activating polypeptide-38 (PACAP-38) for migraine
prevention. For more information, visit www.alderbio.com.
Investor Relations Contact:
Michael SchaffzinStern Investor Relations,
Inc.212-362-1200michael@sternir.com
Media Contact: Ashley
CadleTogoRuna.cadle@togorun.com310.463.0143
Alder BioPharmaceuticals (NASDAQ:ALDR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alder BioPharmaceuticals (NASDAQ:ALDR)
Historical Stock Chart
From Apr 2023 to Apr 2024